Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Weak. Alnylam Pharmaceuticals, Inc. scores higher than 13% of the 1,794 companies Ryufin scores.
Carried by earnings quality, held back by valuation and return on capital.
Healthcare median 27 · all companies 50
26% of the score, 30% here after data gaps
Alnylam Pharmaceuticals, Inc. is valued at 78x its operating profit, including debt: past the 25 times where this criterion gives nothing.
18% of the score, 20% here after data gaps
Over 7 years the business earned -82% a year after tax on the capital it uses.
16% of the score, 18% here after data gaps
No operating profit over the period, so nothing was earned to reinvest.
14% of the score, 16% here after data gaps
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Taken out: its 12% is shared by the others
Margins have been too thin to measure a cycle against.
8% of the score, 9% here after data gaps
What the debt weighs against the profit that has to carry it.
6% of the score, 7% here after data gaps
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For ALNY, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2025-12-31, latest annual report FY2025.